 |
|
 |
- May 17, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"The FIELD Study"Prof. Timothy Davis (biography)
English - 2005-12-07 - 35 minutes
|
 | (43 slides) |
Summary :
The results of the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study were presented at the AHA meeting held in Dallas in November 2005. This was a randomised trial of the effects of fenofibrate on coronary morbidity and mortality in people with diabetes, and in this talk Prof. Davis presents the data and discusses its implications.
Fenofibrate reduces triglycerides, total and LDL cholesterol, and increases HDL cholesterol, and the objective of the FIELD study was to provide the first randomised evidence of the effects of fenofibrate on the risk of major coronary disease events (non-fatal myocardial infarction or CHD death) in patients with type 2 diabetes and not taking statin therapy at study entry. Almost 10,000 patients were randomised to fenofibrate or placebo, with a planned follow-up of at least 5 years or until there had been a minimum of 500 CHD deaths or non-fatal myocardial infarctions.
There was a non-significant relative risk reduction in the primary outcome (CHD death and non-fatal MI) in those assigned to fenofibrate therapy. The relative risk of non-fatal MI by itself was however significantly reduced. The relative risk of the main secondary endpoint, namely total CVD events, was also significantly reduced in the fenofibrate group - interestingly those on active therapy without prior CVD received significant benefit whereas those with prior CVD were at the same risk as those on placebo.
Prof. Davis discusses other secondary and tertiary outcomes, safety data, and how the effects of fenofibrate seemed to be modestly attenuated by differential statin use. In conclusion, says Prof. Davis, the results of the FIELD study are likely to be of particular importance for patients without previous CVD, and where both the prevention of non-fatal macrovascular events and microvascular complications of type 2 diabetes are judged important.
Copyright © 2005 E-MedHosting.com Inc.
Learning objectives :
After viewing this presentation the participant will be able to discuss randomised evidence from the prospective FIELD study:
- Effects of fenofibrate on the risk of major coronary disease events in patients with type 2 diabetes
- Secondary and tertiary outcomes including total CVD events, stroke, progression of renal disease and others
- Safety
- Implications of the data
Bibliographic references :
The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet. 2005 Nov 26;366(9500):1849-61.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
